Tevligraf 0,5 mg/ 1 mg/ 3 mg/ 5 mg Prolonged-release hard capsules.
PDF Leaflet Revision Date: 10 November 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Prophylaxis of transplant rejection in adult kidney or liver allograft recipients.
Dosage (summary)
Initial dose: 0.20-0.30 mg/kg/day for kidney; 0.10-0.20 mg/kg/day for liver, once daily.
Special Populations
- Liver impairment
- Elderly
- Non-Caucasian patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Grapefruit juice
- Ciclosporin
Contraindications
- Hypersensitivity to tacrolimus
- Pregnancy
- Lactation
- Live vaccines
Common side effects
- Tremor
- Renal impairment
- Hyperglycaemia
- Diabetes mellitus
- Hyperkalaemia
Counselling Points
- Take on an empty stomach
- Monitor for signs of infection
- Avoid grapefruit juice
Serious warnings
- Nephrotoxicity
- Increased risk of infections
- Potential for malignancies
Important Disclaimer
The Tevligraf 0,5 mg/ 1 mg/ 3 mg/ 5 mg Prolonged-release hard capsules. professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
